ACURATE neo™

Aortic Valve System

Boston Scientific Clinical Trials

Explore

PROGRESS PVL Registry

The PRospective Observation of aortic reGuRgitation aftEr TAVI and progreSS over time (PROGRESS) PVL registry
- Kim, WK, Presented PCR e-Course June 25-27, 2020

An open-label, single arm study of 500 patients enrolled at 22 centers in Germany, Canada, the United Kingdom, and Italy between January 2017 and July 2018.

The PROGRESS PVL Registry:

Confirms the high procedural success rate, low overall VARC-2 complication rates, and excellent hemodynamic performance of the ACURATE neo Valve Platform seen across multiple studies and registries.
Shows low core-lab adjudicated paravalvular leakage (PVL) rates (4.3% ≥moderate at discharge, 2.9% (at 1-year) and a significant overall improvement between discharge and 1 year in a paired analysis (P<0.001).

PVL, Paired Analysis

(N = 209, core-lab adjudicated)

Hemodynamic Performance

(mmHg/cm², core-lab adjudicated)

SAVI-TF Post-Market Registry

Real-world experience using the ACURATE neo prosthesis: 30-day outcomes of 1,000 patients enrolled
in the SAVI-TF registry
- Möllmann H et al.; EuroIntervention 2018;13:e1764-e1770

One-year outcomes of the european post-market registry using the ACURATE neo transcatheter heart valve under real world conditions in 1,000 patients
- Kim et al.; JACC: Cardiovascular Interventions vol. 11, no.1 4, 2 0 1 8; July 23, 2018: 1368–74

European, single-arm, multicenter, all-comers registry, 1,000 patients from
25 centers in Europe directly following CE-marking of ACURATE neo between
October 2014 and April 2016.